In Brief: Nycomed/Centeon
This article was originally published in The Gray Sheet
Executive Summary
Nycomed/Centeon: Announce letter of intent under which Centeon will gain the exclusive rights to market Nycomed's TachoComb fibrin adhesive product to all countries outside of Europe, excluding Japan and certain other countries. Under terms of the deal, Centeon will make a down payment to Nycomed and contribute to TachoComb's worldwide development. Centeon also will fund and perform clinical development for the product in the U.S. and counties outside of Europe. TachoComb, a collagen fleece coated with a fibrin sealant, complements Centeon's fibrin sealant BeriPlast, both of which are used in tissue sealing and the control of bleeding. FDA currently is reviewing data from overseas trials of BeriPlast to determine whether the information is sufficient to support a premarket approval application or whether additional U.S. trials will be needed, Centeon says...
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.